Performance of a cardiac lipid panel compared to four prognostic scores in chronic heart failure

Area of Science:

• Cardiology
• Metabolomics
• Biomarker Discovery

Background:

• Existing cardiovascular disease risk scores have limitations in precision and applicability to specific populations.
• The cardiac lipid panel (CLP) is a novel metabolomic biomarker panel showing promise for diagnosing and predicting outcomes in chronic heart failure (CHF).

Purpose of the Study:

• To compare the prognostic performance of a risk score utilizing the CLP plus NT-proBNP against four established risk scores in elderly CHF patients.
• To evaluate the ability of the CLP-based score to accurately stratify patients into distinct risk categories.

Main Methods:

• A cohort of 280 elderly CHF patients from the Cardiac Insufficiency Bisoprolol Study in Elderly trial was analyzed.
• Cox Regression and hierarchical cluster analysis were employed.
• Integrated area under the curves (IAUC) was used to compare prognostic accuracy.

Main Results:

• The CLP score demonstrated the highest IAUC (0.78), outperforming Framingham risk score (0.53), Seattle Heart Failure Model (0.61), Meta-Analysis Global Group in Chronic Heart Failure (0.68), and Barcelona bio-HF (0.72).
• The CLP score effectively stratified patients into low, moderate, and high cardiovascular risk clusters.
• The study achieved a mean follow-up of 81 months, with 34% of subjects reaching the primary endpoint.

Conclusions:

• A risk score incorporating the cardiac lipid panel and NT-proBNP significantly outperforms traditional prognostic scores for predicting 10-year cardiovascular death in ambulatory elderly CHF patients.
• This novel metabolomic biomarker approach holds potential for improving clinical risk stratification and management of CHF patients.